[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 1984

A Double-blind Study of Prazosin in the Treatment of Raynaud's Phenomenon in Scleroderma

Author Affiliations

From the Departments of Psychiatry (Dr Surwit and Mr Allen) and Medicine (Drs Surwit, Gilgor, and Duvic), Duke University Medical Center, Durham, NC.

Arch Dermatol. 1984;120(3):329-331. doi:10.1001/archderm.1984.01650390051010
Abstract

• Nineteen patients with Raynaud's phenomenon in conjunction with progressive systemic sclerosis were given either prazosin hydrochloride (1 mg orally three times a day) or a placebo for eight weeks, after which the treatment procedure was reversed for four weeks. Prazosin was shown to be effective in reducing both the frequency and the severity of vasospasm reported by the patients.

(Arch Dermatol 1984;120:329-331)

×